Latest Conference Articles

Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives at the Community Oncology Alliance (COA), discusses upcoming policy initiatives and the current oncology landscape amid a health care cyberattack.

Martina Porter, MD, FAAD, vice chair of research, Department of Dermatology, Beth Israel Deaconess Medical Center, discusses efficacy and safety findings from a phase 2 study.

At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.

Yuqian Liu, PharmD, Magellan Rx Management, explores the current space of cell and gene therapies based on real-world data and potential emerging therapies in the future, while expanding upon long-term efficacy concerns.

Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.

Jenny Craven, PharmD, BCPS, of the University of California Davis Health reviews the finances associated with Emerging Therapy Committee and examines the benefits of the adoption process of new therapies.

Kimberly Westrich, MA, of the National Pharmaceutical Council, addresses the benefits of incorporating patient-centricity throughout the health care system to foster more accurate and better quality of care.

Sarah Bajorek, PharmD, MBA, BCACP, University of California, Davis Health, discusses notable gene therapies emerging into the market and strategies to proactively engage with a wide range of stakeholders during the integration of a new gene therapy.

Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.

Presenters explored the real-world evidence in support of biosimilars at the Academy of Managed Care Pharmacy 2024 annual meeting.

In this interview from our coverage of the 2024 Community Oncology Conference, Shawn Tuma, JD, CIPP/US, Spencer Fane LLP, discusses how he helps clients reduce their cyber risk and be better prepared for breaches when they occur.

Monica Li, MD, medical and cosmetic dermatologist, explained the efficacy and safety differences between radiofrequency microneedling and traditional microneedling.

Lawrence Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital in San Diego, shared the implications of the findings from INTEGUMENT-PED, the phase 3 study assessing the efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients with atopic dermatitis (AD), for future clinical practice.

By prioritizing well-being, both the public and private sectors can come together in partnerships to address social needs and social determinants of health.

Ari Green, MD, University of California, San Francisco, discusses the promising results observed in current remyelination trials in multiple sclerosis (MS) and the patient-specific features that may influence therapy outcomes.

Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health, shares the importance of incorporating a culture of well-being within oncology practices.

As CMS’ suite of value-based and accountable care models evolves, leaders from across the agency detailed how they are working together to streamline quality reporting and encourage the move to a population health mindset while addressing providers’ concerns.

Legal expert in health care, partner, and cochair of the health care coverage and reimbursement practice at Foley Hoag LLP, Ross Margulies discusses his excitement and expectations as a featured speaker at the upcoming 2024 AMCP Annual Conference.

Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, anticipates the 2024 AMCP Annual Conference as an opportunity to engage with fellow managed care pharmacy stakeholders in addressing evolving health policy challenges.

Robert Sidbury, MD, MPH, FAAD, division head of dermatology at Seattle Children's Hospital and professor of pediatrics at the University of Washington School of Medicine, discusses implementing value-based care initiatives in a pediatric dermatology practice.

Mitzi Joi Williams, MD, of Joi Life Wellness Multiple Sclerosis (MS) Center, lists challenges in recruiting and retaining minority populations for clinical trials and discusses ways to ensure clinical trial accessibility.

Accelerated biological aging may be behind why some types of cancer are on the rise in young adults, researchers find.

Lawrence Eichenfield, MD, of Rady Children's Hospital - San Diego, discusses the implications of the findings from INTEGUMENT-PED, the phase 3 study assessing the efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients with atopic dermatitis (AD).

Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health, shares insights on how peer support groups can help manage psychological and emotional distress amid a national drug shortage.

Krystyn Van Vliet, PhD, of Cornell University, discusses the scalability of 3D platforms in multiple sclerosis (MS) drug discovery and compares their costs with those of other drug discovery methods.

The annual legislative update at the Community Oncology Alliance Community Oncology Conference identified what Congress may focus on prior to the upcoming election.

This panel at the Community Oncology Alliance conference discussed the impact of pharmacy benefit manager (PBM) response to the end of direct and indirect remuneration fees, which has been dramatic cuts to cancer drug reimbursement.

"The government really didn't rise to the challenge the way that it should have,” notes Ben Jones, vice president of government relations and public policy for The US Oncology Network. “Practices were in distress…stretching all resources to figure out workarounds."

Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, is 1 of 6 cochairs for the 2024 Community Oncology Conference, and here she discusses how meeting content has incorporated ongoing coverage of the extremely disruptive cyberattack and how there is still so much work to be done.

Jonathan E. Levitt, Esq, founding partner of boutique health care law firm Frier Levitt, LLC, discusses a recent class-action lawsuit brought against Johnson & Johnson in which an employee alleged a breach of fiduciary duty regarding her employer-sponsored pharmacy benefits.